The Core Engine Finally Steps Up, and the Share Price Has Already Spent It

Results vs. Consensus

Q2 FY2027 scorecard: quarter ended September 30, 2026

A second independent consensus panel put adjusted EPS at $10.72 and revenue at $109,896M, which makes the beat +9.0% and +1.0% respectively. We use the primary panel above and note the range. No independent consensus exists for gross profit, segment profit or cash flow, so those rows carry no beat or miss verdict and are shown against the prior-year actual instead.

Year-over-year comparisons

Two structural points sit inside that table. The prior-year quarter included $25M of adjusted operating profit from the Norway business, exited in January 2026, and $51M of net gains on an equity-investment sale and market positions inside The US Oncology Network. Stripping both from the comparison base lifts operating profit growth to 19% and adjusted EPS growth to roughly 24%, which is the figure management quoted. The same arithmetic means the headline 13% operating-profit growth absorbed a $76M profit headwind it will not face again after this fiscal year.

Quarter-over-quarter comparisons

First-quarter figures are derived by subtracting the reported second quarter from the reported six-month columns, which is how the issuer presents its own quarterly cash flow. The sequential tax step down from 21.5% to 17.8% is worth isolating: it contributed roughly $0.55 of the $1.75 sequential EPS increase.

Revenue: volume carrying a price headwind

Revenue of $110,957M grew 8% with every one of the four operating segments contributing, which has not been true in each quarter of our coverage. The composition matters more than the total. North American Pharmaceutical grew 6% while absorbing a roughly 4-point drag from January's branded price reductions, so underlying transaction volume grew closer to 10%. Oncology and Multispecialty grew 24% on specialty distribution and provider-platform volume. Medical-Surgical grew 5%, which management described as a continued sequential improvement in its revenue trend, and which makes the segment's profit decline more awkward rather than less.

The beat against consensus was less than one percent, and one media characterisation of the revenue line as in line rather than a beat is fair. Revenue is not where this company is scored. On a 3.5% gross margin, a one-percent revenue surprise is worth almost nothing; the variance that matters is whether the gross profit dollars per transaction hold.

Margins: the third consecutive quarter of core expansion

The single most important number in the release is 1.14%. That is the North American Pharmaceutical adjusted operating margin, against 0.98% a year ago and 1.03% last quarter. When we initiated coverage in August 2025 the open question was whether scale, specialty mix and automation could convert distribution volume into profit growth faster than branded price deflation eroded it. Q3 FY2026 said no, with a 2 bp contraction. The three quarters since have said yes, by 9 bp, 12 bp and now 16 bp.

The operating-leverage disclosure supports the same reading. Adjusted operating expenses grew 8% against 10% adjusted gross profit growth, improving the expense-to-gross-profit ratio 141 bp. Management attributed the leverage to the core segment specifically and framed it as the yield on a multi-year investment programme rather than a quarter's cost discipline. That is the right frame, and it is the first quarter where the claim is supported by three consecutive data points rather than one.

EPS: good operations, a generous share count, and a helpful tax line

Adjusted EPS of $11.68 beat the primary consensus panel by $0.99, a 9.3% surprise that is large for a distributor. Decomposing it is unflattering in one respect. Adjusted earnings grew 11.1% while the diluted share count fell 6.2%, and holding shares at the prior-year 124.4M would have produced $10.96. So operations delivered $1.10 of the $1.82 increase and the buyback delivered $0.72.

The buyback is real capital return and we do not discount it, but it is finite in a way that margin expansion is not. McKesson spent $3.4B on repurchases in the first half at an average price near $818, which management described as completing a significant portion of the planned full-year $5B. The remaining authorisation will be spent nearer $1,072. Each dollar of buyback now retires 24% fewer shares than the first-half tranche did, so the mechanical EPS contribution decays from here even if the dollar commitment holds.

The tax line deserves equal scrutiny. The 17.8% adjusted rate included $105M of net discrete benefits, about $0.90 per share. Without them the quarter would have run at 23.8%. The full-year guide of 18%–19% is unchanged, and because the first half ran at 19.6%, the second half has to average roughly 17.5% to land there. That is the same back-half-weighted pattern that produced a 12.1% fourth quarter last year, so it is an established practice rather than a surprise. It does mean the full-year EPS bridge depends on discrete items that are, by definition, not operating performance.

Segment Performance

Core margin trend: the question that defined our coverage

Margins are seasonal within the fiscal year, so the year-over-year column is the one that carries information. Read down it and the operating-leverage pillar has gone from unproven to established over five quarters, with one failed test in the middle.

North American Pharmaceutical: the thesis pillar finally clears

Revenue of $91,360M grew 6% and adjusted operating profit of $1,040M grew 22%, a spread of 16 points between profit and revenue growth that is the entire investment case for a distributor. The profit growth came from specialty distribution into health systems and strategic accounts, not from the GLP-1 line, and management was explicit that the January price reductions hit revenue and not profit for the third consecutive quarter.

The CFO's own decomposition is worth quoting because it names the mechanism rather than the result.

"When you parlay a strong, healthy, broad based growth with continued operational excellence, and productivity within our supply chain ecosystem, we saw really nice operating leverage close to a 150 bps, which was led by our North America pharmaceutical business." — Kenny Cheung, EVP and CFO

Two forward items attach to this segment. The pharmaceutical distribution relationship with CVS Health was extended through June 2032, with the new term starting October 1 and already inside the guidance. And the full-year segment profit guidance went to 14%–18% from roughly 9.5%, a midpoint increase of about six and a half points, or roughly $224M of segment profit on the fiscal 2026 base.

Assessment: Bull pillar one is now confirmed on three consecutive quarters and stays ON TRACK. The caution is arithmetic rather than qualitative: the first half grew 21% and the raised full-year guide implies 8%–15% in the second half, because management is deliberately accelerating investment. Do not extrapolate 22%.

Oncology & Multispecialty: 24% revenue growth, 8% reported profit growth, 23% underlying

This segment's optics are the worst in the release and its substance is fine. Revenue grew 24% to $14,980M while adjusted operating profit grew only 8% to $427M, compressing margin 45 bp to 2.85%. The gap is the $51M of net gains inside the prior-year base. Excluding them, profit grew 23%, roughly in line with 24% revenue growth.

The operating detail is encouraging. Management reported same-store patient visits at their highest level in recent quarters, provider platform expansion through both existing-practice growth and new additions, and more than 3,400 providers in The US Oncology Network. PRISM Vision Group added Spectrum Vision Partners on November 2, taking its network past 350 providers from a base of roughly 200.

This is also where the newly closed Precision Medicine Group will report, and where the segment's margin mix should begin to improve structurally rather than cyclically.

Assessment: The $51M gain lap we flagged as a watch item last quarter arrived and was handled cleanly, with management disclosing the underlying 23% unprompted. Bull pillar two stays confirmed. The remaining gap in disclosure is the same one as last quarter: the split between same-practice growth and acquired or added providers is still not given, so the organic rate inside the 23% is an inference rather than a disclosure.

Prescription Technology Solutions: best margin expansion in the portfolio

Revenue of $1,520M grew 10% and adjusted operating profit of $307M grew 18%, expanding margin 123 bp to 20.20%. Growth came from access solutions, specifically prior-authorisation services, with contributions from the CMS Medicare GLP-1 bridge programme that began July 1. The platform added 67 new programmes across 58 unique brands in the quarter, and management introduced medical prior-authorisation capabilities.

Management also volunteered the deceleration, which we credit.

"For example, we are in the early phases of supporting the CMS Medicare GLP-1 bridge program. Following initial strong demand, prior authorization volumes have begun to normalize, and we will continue to monitor trends as the program progresses." — Kenny Cheung, EVP and CFO

Assessment: Bull pillar three stays confirmed, and the 123 bp of margin expansion is the clearest evidence yet that this is network economics rather than logistics volume. The unprompted normalisation disclosure is why we are leaving full-year guidance at the midpoint rather than the high end despite 15% first-half growth: the segment's own guide of 11%–15% implies 7%–15% in the second half, and the fourth-quarter recertification seasonality is the swing factor.

Medical-Surgical Solutions: the revenue recovery still has not reached earnings

Revenue of $3,097M grew 5%, continuing a sequential improvement in revenue trend, while adjusted operating profit of $225M fell 10% and margin compressed 118 bp to 7.27%. Management attributed the decline to product mix in the ambulatory care channel, partly offset by extended care. Full-year segment profit guidance was cut from flat-to-4% growth to a 4% decline-to-flat range.

"Moving now to MedSurg, We anticipate revenue growth of 1% to 6% and operating profit to range from a 4% decline to flat." — Kenny Cheung, EVP and CFO

Even that reduced guide requires a sharp inflection. First-half profit fell 14.8%, so the full-year range implies second-half growth of 6.0% to 13.6%. The swing factor management named is the annual illness season, which it also described as varying in timing, severity and duration from year to year.

Assessment: This is the second consecutive fiscal year in which Medical-Surgical profit disappoints into a separation it is supposed to be prepared for, and the fourth consecutive quarter in which segment revenue rose while profit fell. Bear pillar risk here is no longer about the illness season. A business whose earnings fall while its sales rise is being separated at the wrong point in its own cycle, and nothing on this call addressed that.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: The most confident posture of our coverage, and for the first time the confidence rests on delivered results rather than on a forward framework. Prepared remarks led with strategy and transactions before numbers, which is what a management team does when the numbers are not in question. The one place the tone turned careful was the long-term growth algorithm, where repeated pressure to raise it produced a framework-level restatement rather than a number, and the one place it went quiet was the Medical-Surgical separation, which went unaddressed by anyone.

1. The core distribution engine steps up, and the guidance follows

North American Pharmaceutical full-year adjusted operating profit guidance moved to 14%–18% growth from the high end of a 5.5%–9.5% range. That is a revision of roughly six and a half points at the midpoint on the segment that produces more than half of consolidated profit, and it is the main reason the consolidated EPS guide moved $1.40.

Management framed the result as a cumulative payoff rather than a quarter.

"I just wanna reflect on, you know, I think the performance we are enjoying is a culmination of years of focus on our strategic priorities years of investment in technologies, whether that is physical, distribution or robotic process automation or now large language models in AI, they are translating from the gross profit you know, leverage ratios that Kenny reviewed." — Brian Tyler, Chair and CEO

We would attach one qualifier to the technology framing. First-half capital expenditure was $275M against $385M a year ago, down 29%, while management describes accelerating investment. The investment being referenced is largely in the expense line rather than the capital account, which is consistent with software and process rather than physical automation, and which is also why it compresses second-half margins.

Assessment: The pillar is proven and the guidance now reflects it. Our fiscal 2027 segment estimate rises $224M, worth $1.57 per share, which is the largest single contributor to our revision. The risk has shifted from whether the leverage exists to whether the market has already capitalised it.

2. Management declines, twice, to raise the long-term algorithm

This was the most informative exchange of the call and it produced a negative answer. With fiscal 2027 guided to 17%–19% adjusted EPS growth, and 19%–21% excluding the Norway and gain laps, against a long-term target of 13%–16%, two separate lines of questioning invited management to move the target. It did not.

"I just remind you that our long term targets are long term in nature, not an indicator of short term variations that incur that can occur within the business year to year." — Kenny Cheung, EVP and CFO

Management's own guidance language made the same point in the other direction, noting the implied growth sits "well above our long term growth target of 13% to 16%." A company that believed its run rate had permanently repriced would have used this call to say so. The September 2025 investor day raised the algorithm from 12%–14% to 13%–16%, so there is recent precedent for revising it when management believes it.

Assessment: We take management at its word, and our fiscal 2028 forecast of 13.4% growth sits at the low end of the stated range accordingly. This is the fulcrum of the rating. If the correct fiscal 2028 number is 13%–16% rather than a continuation of 17%–19%, then today's multiple is paying for an acceleration that the people running the business have twice declined to endorse.

3. Precision Medicine Group moves oncology up the margin curve

The $2.25B acquisition of Precision Medicine Group closed November 2, two days before the print and after the quarter end, so none of it appears in these statements. It reports inside Oncology & Multispecialty and comprises two parts: Precision for Medicine, a global clinical research and laboratory business with oncology trials in more than 30 countries, and Precision AQ, a market access and commercialisation services platform.

"We estimate the acquisition will contribute approximately $0.10 to $0.20 of adjusted earnings per diluted share in fiscal 2027 with contributions more heavily weighted towards the fourth quarter. By the end of year 3, we estimate accretion of approximately $1.60 to $1.80" — Kenny Cheung, EVP and CFO

Management placed the business on the higher-margin end of the portfolio chart it has used since its investor day, alongside data services and clinical research rather than distribution and group purchasing. It was funded entirely with cash, which explains the $6,528M cash balance built during the quarter.

Assessment: Strategically coherent and well placed against the existing SCRI joint venture. Financially, the year-three accretion of $1.60 to $1.80 is roughly 3.3% of our fiscal 2028 base, and reaching it requires synergies management described but did not size. We carry the fiscal 2027 contribution inside the guided range and lift our fiscal 2028 oncology growth assumption one point to 15.5% for the annualisation. We do not capitalise the year-three figure.

4. Option Care Health is an incubated option, not a consolidated business

On October 5 McKesson agreed to invest roughly $1.4B for approximately 49% of Option Care Health, the largest independent home and alternate-site infusion provider. CD&R will own the majority at closing, expected in the first half of calendar 2027. It will be accounted for under the equity method, appearing in other income within the corporate segment rather than in any operating segment's margin, and it is explicitly excluded from the current outlook.

"And so I very much think of this as incubating future growth platforms highly adjacent to our core strategy." — Brian Tyler, Chair and CEO

Management was candid that it is the non-operating partner, that the business has been under CD&R stewardship for years, and that there are no commercial interfaces today because the transaction has not closed. One analyst referred to a call option on the remainder, which management did not address.

Assessment: The strategic logic on site-of-care migration is sound and the structure is honest about McKesson's role. For valuation purposes it is a $1.4B cash outflow with an unquantified earnings contribution and no control, so we exclude it from our forecast exactly as management excludes it from guidance. It is genuine optionality and we will not pay for it in advance. Four of the seven questions on the call touched these two transactions, which tells you where the Street's attention has moved.

5. GLP-1 distribution passes $16 billion with the profit still undisclosed

GLP-1 medication distribution revenue reached $16B, up approximately $3B or 26% year over year and 8% sequentially. That is roughly 17.5% of North American Pharmaceutical revenue and about 14% of consolidated revenue.

"Demand and volumes across the category remained strong, with quarter to quarter variability based on payer dynamics and patient utilization." — Kenny Cheung, EVP and CFO

This is the sixth quarter of our coverage in which a revenue line of this size is quantified only verbally, and its profit contribution has never appeared in a filed document. The bear concern we have carried since initiation was that GLP-1 mix dilutes reported margin. The core margin has now expanded for three consecutive quarters while this line grew 26%, which is strong evidence against the dilution thesis.

Assessment: Bear pillar one stays contained and the evidence for it keeps weakening, which is a credit to the fee-for-service model. The disclosure gap remains unreasonable. A category at 14% of consolidated revenue with undisclosed channel economics is a line investors have to take on trust, and after six quarters that is a choice rather than an oversight.

6. Access economics expand while the Medicare bridge already normalises

Prescription Technology Solutions expanded margin 123 bp, the widest in the portfolio, on prior-authorisation demand including the CMS Medicare GLP-1 bridge programme that launched July 1. Management reported growth across both GLP-1 and non-GLP-1 therapeutic categories and the addition of 67 programmes across 58 brands.

It also told the market, unprompted, that bridge-programme prior-authorisation volumes have begun to normalise after initial strong demand. Full-year segment guidance was left unchanged at 11%–15% profit growth despite 15% first-half growth, which is management declining to extrapolate its own best segment.

Assessment: Both facts are to management's credit and both argue against raising our estimate. We hold the segment at 13% for the year. The structural point stands: margin expansion of 123 bp on 10% revenue growth is network economics, and it is the part of the portfolio least exposed to drug pricing.

7. 340B and the first post-election policy read

The midterm election fell the day before the call, and the policy question drew answers from both executives. Management identified a potential January 2027 implementation of a 340B rebate model, alongside outpatient prospective payment system changes, and was straightforward that the behavioural response of covered entities is unknowable today.

"At this time, we do not anticipate any material financial impact to our business." — Kenny Cheung, EVP and CFO

On the broader environment the CEO said his view of the policy discussion was unchanged from the prior quarter after twelve hours to absorb the results. The structural defence offered was channel neutrality: whatever happens to where a 340B script is filled, McKesson is represented in every channel that could receive it.

Assessment: This is a genuine reduction in the policy overhang we have carried as a bear pillar since initiation, and we are moving bear pillar two from emerging to contained. Two caveats keep it on the list. A no-material-impact statement covers McKesson's distribution economics, not its customers' viability, and the rebate model's cash-flow burden falls on covered entities who are also McKesson customers. And the 340B services business, consulting and software, is not sized, so an upside case there is not quantifiable either.

8. Medical-Surgical guidance comes down, and the separation goes unaddressed

The segment's profit guidance was cut by four points to a 4% decline-to-flat range. More striking is what nobody said. The Medical-Surgical separation is the largest discrete catalyst in this equity story, carrying a Wellverse brand transition scheduled for January 2027, an IPO structure, a 2H CY2027 full-separation objective set in November 2025, an unsized stranded-cost figure, and the Apollo minority stake behind most of the increase in redeemable interests to $2,563M. Neither executive mentioned any of it in prepared remarks beyond a single clause on interest expense and a note that the minority-interest guidance includes Apollo's stake, and no analyst asked.

"Interest expense was $103 million reflecting financing activities completed in support of the plan medical surgical solution separation." — Kenny Cheung, EVP and CFO

Apart from the Apollo reference inside the minority-interest guidance, that clause is the only reference to the separation on the entire call. The cost of the separation financing is now visible in the income statement every quarter, at 51% year-over-year interest growth, while the proceeds and the endpoint remain undelivered.

Assessment: Bull pillar four stays at risk and we are not moving it. With the brand transition two months away, silence is a meaningful signal, and the segment's deteriorating earnings make the eventual valuation worse rather than better. The financing costs are recurring and in our numbers; the realisation is not and will not be until terms exist.

9. The cash statement improves on payables, and the guidance does not move

Second-quarter free cash flow was $2,947M, which looks transformative until the first half is read as a whole. Half-year free cash flow was $2,575M against $1,117M, up 131%, but net working capital swung $1,240M favourably and that is 85% of the $1,458M improvement. The drafts and accounts payable line alone contributed $7,797M against $5,170M, a $2,627M year-over-year swing. Lower capital expenditure supplied another $110M.

"As a reminder, cash flow can vary from quarter to quarter based on timing, including the day of the week a quarter ends." — Kenny Cheung, EVP and CFO

Full-year free cash flow guidance is unchanged at approximately $4.5B to $4.9B. With $2,575M banked, that implies $1,925M to $2,325M in the second half against $4,293M a year ago, a decline of 46% to 55%.

Assessment: Management is telling you not to annualise the quarter, and it is right. This is the third consecutive quarter where we have asked whether working-capital improvement persists beyond supplier-payment timing, and the answer is still that we cannot tell, because the company guides a full-year number it will not raise and provides no bridge from its working-capital programmes to that number. Cash conversion remains the weakest-supported part of the bull case, and it is why we are unwilling to pay a premium multiple on reported earnings.

10. The share count is doing 40% of the earnings work

Diluted shares fell 6% to 116.7M, contributing $0.72 of the $1.82 adjusted EPS increase. The first half consumed $3.4B of a roughly $5B full-year programme at an average price near $818, funded in part by the Medical-Surgical financing and the Apollo proceeds.

Two things follow. The remaining buyback executes at a price roughly 31% above the first-half average, so the share reduction per dollar deployed falls materially. And $3.65B of cash is now committed to Precision Medicine Group and Option Care Health, which competes directly with repurchase capacity in a year where guided buybacks already exceed guided free cash flow.

Assessment: We model 116.5M shares for fiscal 2027 at the guidance midpoint and 113.0M for fiscal 2028, which assumes continued repurchase at a reduced pace. The mechanical EPS tailwind from the share count is the most reliable component of near-term growth and the least durable. Investors paying 20x forward earnings should be clear that roughly seven points of this quarter's 18% EPS growth are a financing decision rather than a business result.

11. The customer base is locked further out than the forecast

The pharmaceutical distribution relationship with CVS Health was extended through June 2032, with the new term starting October 1 and already reflected in guidance. Management described the renewal alongside a broader pattern of customer wins and renewals supporting the second-half outlook.

"This agreement reflects the strength of our long standing partnership more than 25 years, the value of our distribution capabilities, and our ability to support customers at scale reliability, efficiency, and service excellence." — Brian Tyler, Chair and CEO

Assessment: Underrated in the day's coverage. Customer concentration is the structural fragility of pharmaceutical distribution, and removing renewal risk on a top customer for five and a half years is worth more to the durability of the earnings stream than either acquisition announced this quarter. It is the main reason we raised our fiscal 2028 core growth assumption to 7.0% from 6.5% despite expecting deceleration from fiscal 2027's pace.

Guidance & Outlook

This is the cleanest guidance revision of our coverage and the opposite of the fiscal 2026 first-quarter raise, which was entirely Norway held-for-sale accounting. Every dollar of the $1.40 comes from operations, and the segment detail shows where: the core and oncology profit ranges moved up by six and a half and four and a half points respectively, while two cost items, corporate expense and interest, were quietly moved to their unfavourable ends. Management did not pretend otherwise.

"Our updated outlook implies adjusted EPS growth of 17% to 19%, excluding the impact of the Norway divestiture and the net gains within the U.S. Oncology Network in fiscal 2026, our outlook implies adjusted EPS growth of 19% to 21% which is well above our long term growth target of 13% to 16%." — Kenny Cheung, EVP and CFO

Implied second-half ramp

First-half adjusted EPS of $21.59 against a $45.60 to $46.40 full-year range implies $24.01 to $24.81 in the second half, against $20.99 a year ago. The shape is coherent: management has told you repeatedly that it is accelerating investment in the second half, and the deceleration in three segments is that investment. The outlier is Medical-Surgical, which has to swing more than 20 points from a 15% first-half decline, and the stated swing factor is an illness season management explicitly declined to predict.

Street at: The new $45.60 to $46.40 band sits $1.40 above the prior $44.20 to $45.00 guidance range, so we expect near-term estimate revisions to be upward. Published price targets moved up materially on the day, with the trailing published average still below the current share price.

Guidance style: Conservative and getting more so. McKesson has raised its fiscal 2027 range twice, from an initial $43.80 to $44.60, to $44.20 to $45.00, to $45.60 to $46.40. It left RxTS and Medical-Surgical revenue ranges untouched after a strong first half in the former, put corporate and interest at their unfavourable ends, and held free cash flow despite a $2.9B quarter. A management team guiding a company toward a 23x multiple would do the opposite. The pattern of under-promising is itself a reason to expect the operating results to keep beating, and a reason not to assume the guidance range is the ceiling.

Analyst Q&A Highlights

Question and answer ran seven questions, unusually short, and four of the seven touched the two announced transactions. That concentration is itself the story of the session: the Street spent most of its time on capital deployment, two questions pressed on whether the core earnings step-up is durable, and none touched the cash statement or the pending separation.

Where the two new businesses land, and what they do to segment margins

The opening question went straight to reporting mechanics and margin mix, asking how two newly acquired businesses would thread through the segment structure and what that implies for modelling the calendar year ahead. The answer was specific and useful: the clinical research and market access businesses both report inside Oncology and Multispecialty, the infusion stake sits in other income within corporate under the equity method and touches no segment margin, and management placed the acquired businesses on the higher-margin side of its own portfolio chart.

Q: "I am trying to understand these 2 acquisitions you did Precision Medicine Group and Option Care Health. I am just trying to I want to make sure I am clear on how these businesses will weave through the reporting segments of the company and the potential impact that may have on your margins."
— Glen Santangelo, Barclays

A: "if you remember at our Investor Day a couple of years ago, we laid out kind of on the left side of the slide distribution and GPO with lower margin as you progress into data service and FCRI, those tend to be higher margin, more complement. More higher margin businesses. And we would put we would put PMG more on the right side of the chart."
— Brian Tyler, Chair and CEO

Assessment: A clear answer to the part that was asked. The second half of the same question, on the margin consequences across oncology and prescription technology of the biosimilar wave arriving over the next twelve months, was never addressed by either executive. That omission is the most substantive dodge of the call, and it went unchallenged because the questioner did not get a follow-up.

Whether the core segment's outperformance is sustainable

The second line of questioning put the central issue squarely: the core distribution segment is growing far in excess of its own long-term guide, and has been for several quarters, so what should be assumed beyond this year. The response decomposed the quarter thoroughly, named broad-based volume, specialty, GLP-1 and supply-chain productivity as the drivers, and then described the second half in terms of investment and customer renewals rather than offering a durable rate.

Q: "Given the outperformance in North American pharma, obviously growing well in excess of the long term guide there. How do we think about the sustainability of that over the long term?"
— Elizabeth Anderson, Evercore ISI

A: "So overall, we are really pleased with the growth the momentum, and the durable profile of this business. As I think through the second half of the fiscal year, the outlook reflects continued broad based strength across the business."
— Kenny Cheung, EVP and CFO

Assessment: The word "durable" was used and then not quantified. Management answered a question about the long run with a description of the current year. For a reader trying to set a fiscal 2028 core growth rate, the only usable guidance remains the 5% to 8% segment long-term range, which is less than half of what the segment is currently doing.

Why the long-range plan is not moving

The same issue returned immediately in blunter form, with a questioner characterising the long-range plan as far too low relative to delivered results and asking, in effect, what would have to go wrong for the core segment to grow only as fast as the plan says. The response restated the 13% to 16% consolidated EPS target, expressed confidence in executing against it, and closed by distinguishing long-term targets from year-to-year variation. No revision was offered.

Q: "your LRP versus what you have done over the last year or 2 or so seems comically low. So maybe instead of asking what drove you to get to in this quarter north of 20% EBIT growth, Maybe what needs to happen for you to actually grow North American pharma inside the LRP?"
— Kevin Caliendo, UBS

A: "I just remind you that our long term targets are long term in nature, not an indicator of short term variations that incur that can occur within the business year to year."
— Kenny Cheung, EVP and CFO

Assessment: The most consequential answer on the call. Management was offered two chances to tell the market its growth rate had permanently stepped up and declined both, having raised the same algorithm barely a year earlier when it did believe it. Read plainly, this is management saying the current pace is variation rather than a new baseline. Any valuation that extrapolates fiscal 2027 growth is arguing with the company.

What 340B implementation does to volume, and the first post-election read

The policy question came the day after the midterm election and drew answers from both executives. The substantive content was an admission that the behavioural response of covered entities to a January 2027 rebate model is unknowable, paired with a structural argument that channel neutrality protects the script wherever it migrates. The financial conclusion was stated flatly and separately.

Q: "Brian, you talked about a dynamic policy environment. can you maybe just update us on any of your thoughts now, that we have an idea of what Congress is going to look like going into 2027? Any changes that you are anticipating that could impact either side of your business?"
— Lisa Gill, JPMorgan

A: "You know, the thing for us is we are represented in all channels, and what we know is the script will still be there, and we will be ready to receive it in support of in whatever channel we can."
— Brian Tyler, Chair and CEO

Assessment: The strongest answer of the call because the argument does not depend on predicting policy. Channel neutrality is a real structural defence and it is why we are reducing the policy risk in our thesis. Note what the answer does not cover: the rebate model's cash burden falls on covered entities who are also customers, and customer viability is a separate exposure from distribution economics.

Integration risk in two unfamiliar businesses

One line of questioning tested the capital-deployment shift, noting that recent acquisitions had been practice-management and specialty assets in businesses the company already understood, while a contract research organisation and an infusion provider are not. The answer drew a distinction between integration and addition, arguing the acquired capabilities are adjacent rather than overlapping and will be offered alongside existing services rather than merged into them.

Q: "Can you talk about the relative complexity of integration of EMG and Option Care relative to what we have seen over the past couple years, growing that US oncology business growing the retina business, Is there a delta there?"
— Allen Lutz, Bank of America

A: "So we will be very thoughtful about how we, quote, unquote, integrate the business. But these are highly complementary businesses with very little overlap."
— Brian Tyler, Chair and CEO

Assessment: Credible on the commercial logic and quiet on the cost side. "Very little overlap" is a reason to expect low disruption and also a reason to doubt large cost synergies, which is awkward given that year-three accretion of $1.60 to $1.80 was presented as including assumed cost synergies. Both statements can hold only if most of the accretion is revenue-driven, which is the harder kind to deliver.

Whether the infusion stake is a commercial relationship or a financial one

The final question pushed on whether the minority investment is really an operating partnership with procurement and contracting value, or simply an equity-method holding, and asked directly whether supplier arrangements already exist. The answer was unusually clean: the transaction has not closed, no commercial interfaces exist today, the business will be run by its majority owner, and the holding is best understood as incubation of a future platform.

Q: "Should we think of this as an operating partnership with CD&R where you could come in and do something on procurement and contracting and drive value? Or is this primarily an equity method investment? And are there currently any supplier arrangements between McKesson and Option Care?"
— Dylan Finley for Michael Cherny, Leerink Partners

A: "So first, the Option Care deal transaction has not closed. So we are still waiting approval from their shareholders as well as the regulatory agencies. So there are no interfaces ongoing today."
— Brian Tyler, Chair and CEO

Assessment: Exactly the right answer and it closes the question for modelling purposes. There is no near-term procurement synergy to forecast, no consolidated revenue, and no earnings contribution in guidance. Anyone building the stake into near-term estimates is ahead of both the regulators and the company.

What They're NOT Saying

1. The Medical-Surgical separation, in its entirety. The Wellverse brand transition is scheduled for January 2027, roughly two months out. Neither executive mentioned the separation in prepared remarks except as the cause of higher interest expense and, indirectly, through Apollo's stake inside the minority-interest guidance, no analyst asked, and the call produced no update on IPO timing, terms, stranded costs or the 2H CY2027 full-separation objective set a year ago. The costs are recurring and visible; the proceeds and the endpoint are neither.
2. The biosimilar margin question. It was asked explicitly, naming the twelve-month launch slate and the two segments exposed, and it was not answered by either executive. For a company whose generics and specialty economics drive the core margin thesis, an unanswered question on the next wave of molecule conversions is a material gap.
3. Any dollar figure for the second-half investment step-up. Accelerated investment is the stated reason three segments decelerate in the second half and the reason the core cannot repeat 22%. Without a size, the raised guidance can be tested against the full-year bridge but not separated into recurring operating momentum and timing. This is the second consecutive quarter we have asked.
4. Profit by GLP-1 channel. Six quarters of a revenue line now at $16B, quantified only on calls and never in a filed document, with no disclosed profit contribution. The core margin expansion is strong indirect evidence the economics are fine, which makes the continued silence harder to justify rather than easier.
5. A bridge from working-capital programmes to the cash guidance. Free cash flow guidance was held at $4.5B to $4.9B after a $2,947M quarter, implying a 46% to 55% second-half decline. Management said not to annualise and gave the day-of-week explanation, but offered no reconciliation between its stated working-capital initiatives and an unchanged annual number.
6. The settlement timing of redeemable minority claims. Redeemable noncontrolling interests sit at $2,563M, unchanged sequentially, with no cash-payment schedule. The balance and its remeasurements are disclosed; the obligation's timing is not, and it is a claim ahead of common shareholders.
7. Same-practice versus added-provider growth in oncology. Management disclosed 23% underlying profit growth and that patient visits hit a recent high, both of which help. The split between growth inside existing practices and growth from recruiting new ones is still absent, so the organic rate remains an inference.
8. Any quantification of Option Care Health. Excluded from guidance, which is appropriate. Also unquantified as to expected equity-method income, the terms of the call option on the remainder that an analyst referenced, and the governance rights referenced on the call.

Market Reaction

• Pre-print setup: MCK closed November 4 at $1,069.44, up 30.4% year to date, 16.8% over thirty days and 27.1% over twelve months. Its preceding 52-week closing range was $725.17 to $1,069.44, so it entered the print at the very top of its own range. The S&P 500 was up 12.3% year to date.
• The print-day move came before the print. The shares rose 6.98% during the November 4 regular session, from $999.62 to $1,069.44, hours before the after-the-close release. Two distribution peers reported into that same session and the group moved together, gaining 3.96% and 3.55%. None of the November 4 move is attributable to McKesson's own results.
• Reaction session, November 5: Opened at $1,085.84 (+1.5%), traded as high as $1,121.50 (+4.9%), and closed at $1,072.00, up 0.24% or $2.56. The close was the session low.
• Participation: Volume of 1.3M shares against a 0.7M thirty-day average, 1.8 times normal.
• Against the tape: The S&P 500 fell 4.36% on November 5, its worst session since April 2025, with all eleven sectors lower. MCK's +0.24% is 4.60 percentage points of relative outperformance. Among distribution peers the group again split, one gaining 2.25% and one falling 4.04%.

Two readings of the session are both true and point opposite ways. On a day when the broad market fell more than four percent and every sector declined, a healthcare distributor closing higher on 1.8 times volume is a clear statement of relative strength, although one distribution peer also rose 2.25% that day without a print of its own, so part of the outperformance was sector rotation. Relative to the tape, this was an excellent reaction to an excellent quarter.

On an absolute basis, the shares gave back a 4.9% intraday gain to finish at the session low, and finished only $2.56 above a pre-print level that had itself been marked up 7% in the previous session on somebody else's results. The quarter beat by nine percent on earnings, raised full-year guidance by $1.40, and moved the stock two dollars and fifty-six cents. That is what it looks like when a result is already in the price.

We separate the market-wide explanation from the stock-specific one deliberately. The November 5 decline is widely attributed to weakness in technology and artificial-intelligence related shares following the midterm results, which has nothing to do with McKesson and everything to do with why a defensive distributor outperformed. The absence of an absolute re-rating on a nine-percent earnings beat is the McKesson-specific fact, and it is the one that matters for the rating. The pre-print setup, at the top of a 52-week range after a 16.8% thirty-day advance, is the reason.

Street Perspective

Debate: Has the core earnings algorithm permanently repriced?

Bull view: Three consecutive quarters of core margin expansion, a six-and-a-half-point guidance raise on the segment, and demonstrated operating leverage of 141 basis points mean the 5% to 8% long-term core range is stale. The bull case on the Street is that the company is structurally under-guiding and the algorithm will be raised at the next investor day.

Bear view: The company itself refused to raise the algorithm when asked twice, and the second-half guidance embeds a deceleration to 8% to 15% in the core precisely because investment resumes. One year of exceptional results against an easier comparison base is not a repricing.

Our take: The bears have the better of this because management is on their side. The step-up in demonstrated leverage is real and we have raised our fiscal 2028 core assumption for it, but to 7.0%, not into the teens. The company has a recent track record of raising its algorithm when it believes a change is durable, and it chose not to here.

Debate: Does the capital deployment create value or consume the buyback?

Bull view: Two transactions move the portfolio up the margin curve into clinical research, market access and home infusion, with year-three accretion from the larger one worth roughly three percent of earnings and what one analyst described as a call option on the infusion asset. The Street's optimistic camp reads this as a growth runway extension bought at reasonable prices.

Bear view: $3.65B of cash is committed in a year where guided repurchases already exceed guided free cash flow, the infusion stake is a non-controlling position with no disclosed earnings and no closing date, and the accretion path depends on synergies management declined to size in businesses it described as having very little overlap.

Our take: Both transactions are strategically defensible and neither is yet a valuation input. We carry the guided fiscal 2027 contribution, annualise it modestly into fiscal 2028, exclude the infusion stake entirely as management does, and raise our interest and corporate expense assumptions for the cash that left. The honest position is that this is reasonable capital allocation whose returns are unknowable today.

Debate: Is reported earnings quality good enough for a 20x multiple?

Bull view: The operating line is pristine: volume-led revenue growth absorbing a four-point price headwind, 141 basis points of expense leverage, a third consecutive quarter of core margin expansion, and $50M of settlement gains excluded rather than banked. Earnings of this quality on a recession-resistant, policy-insulated business deserve a premium to a distributor's historical multiple.

Bear view: Forty percent of the earnings-per-share growth came from the share count, the tax rate carried $105M of discrete benefits worth about ninety cents, cash flow guidance was unchanged despite a $2.9B quarter because 85% of the improvement is payables timing, and interest and minority expense are permanently higher. The business is excellent; the reported earnings per share flatter it.

Our take: The bears are right about the composition and the bulls are right about the direction. Our resolution is the multiple, not the estimate: we take the guidance at face value and raise our forecast, then decline to pay more than 20 times for earnings whose growth is 40% financed and whose cash conversion remains unbridged after three quarters of asking. If cash conversion were demonstrated independently of payables timing, we would pay 22 times and the rating would be different.

Our Estimates & Valuation Framework

Our fiscal 2027 bridge gives $45.93, which we round to a $45.90 estimate, up $1.30 from $44.60. Segment growth sits at the guidance midpoint for the core, oncology and prescription technology. Medical-Surgical is held at a 3% decline, below the midpoint of its reduced range, because first-half profit fell 14.8% and the implied second-half inflection depends on an illness season management declined to forecast. Corporate expense and interest are both taken at the guided high end, as directed. The resulting 13.8% operating profit growth sits inside the new 12% to 16% range and the EPS sits inside the new guidance band.

The revision decomposes as follows, with per-share effects after tax at 18.5% over 116.5M shares.

FY2028 operating assumptions. Our estimate uses 7.0% core pharmaceutical profit growth, up from 6.5% last quarter for the demonstrated leverage and the CVS renewal running to June 2032, but far below fiscal 2027's roughly 16%. Oncology grows 15.5%, raised one point to annualise Precision Medicine Group against fiscal 2027's partial and fourth-quarter-weighted contribution. Prescription technology grows 11.5% and Medical-Surgical 2.0%. Corporate expense rises to $660M and interest to $430M because $2.25B of cash funded one acquisition and roughly $1.4B is committed to the other. Tax remains 18.5%, adjusted minority expense rises to $330M, and shares average 113.0M. Option Care Health earnings are excluded, matching management's own treatment. These are our assumptions, not company guidance. The resulting 13.4% EPS growth sits at the low end of the company's 13% to 16% long-term algorithm, which is the algorithm management twice declined to raise on this call.

Twelve-month return cases from the November 5 close of $1,072.00

Target bridge. Our twelve-month value rises from $955.13 to $1,041.40, an increase of $86.27. Rolling the fiscal 2028 estimate from $50.27 to $52.07 at the prior 19x multiple adds $34.20. Raising the multiple from 19x to 20x adds a further $52.07. So 60% of the target increase is the multiple, which is a judgment, not an earnings fact, and we state it plainly rather than burying it in a target change. We raise the multiple one turn because the core margin thesis has now cleared three consecutive quarters and the 340B exposure was explicitly characterised as immaterial. We stop at one turn because management capped its own long-run algorithm and the cash-conversion question is unanswered.

Why the rating moves even though the estimate rose. Two checks make the position concrete. On the same earnings year, 20x our fiscal 2027 estimate of $45.93 gives $918.60, which is 14.3% below today's price, so the current quote already requires the roll to fiscal 2028 plus a full multiple turn. And for the shares to deliver the 8% total return we assume for the broad market, they need $1,153.86 in twelve months, which is 22.2x our fiscal 2028 estimate. The stock has advanced 23.0% since our last report's $871.38 reaction close while our fiscal 2028 estimate rose 3.6%. Price has moved roughly six times faster than earnings expectations.

Downside case. The bear case assumes core profit growth falls to 3.5% as fee or mix pressure finally reaches earnings, oncology grows 11%, prescription technology 8%, and Medical-Surgical falls 5%. Corporate expense of $690M, interest of $460M, a 19% tax rate, $350M of minority expense and 116.0M shares give $47.48. At 17x that implies roughly 24% downside including dividends. Note that the bear case still has earnings growing: the loss comes from multiple compression on a stock priced for continuation.

Upside case. The bull case uses 10%, 19%, 14% and 5% segment growth respectively, with $640M corporate expense, $410M interest, an 18% tax rate, $315M of minority expense and 111.0M shares, giving $55.57. At 22x that implies 14.4% including dividends. This is the case where the long-term algorithm really has repriced, cash conversion proves independent of payables timing, and the separation delivers terms. It requires management to be wrong about its own company in a favourable direction.

Rating support. Our base total return of 2.5% negative, including four dividends at the $0.94 rate stepping to roughly $1.08 next July, compares with an unchanged 8% assumption for the broad market. That is a shortfall of more than ten points, with a 24% downside case against a 14% upside case. The asymmetry is what moves the rating rather than any deterioration in the business. For reference, a $100M recurring pretax cost would reduce our fiscal 2028 estimate by $0.72 and value by $14.43 at 20x, so the separation's unsized stranded costs remain a live claim on the base case.

Thesis Scorecard Post-Earnings

Overall: The thesis is strengthened and the stock is less attractive, which is an uncomfortable pair to hold and the honest reading of this quarter. Three of four bull pillars are confirmed on their strongest evidence in six quarters of coverage, and the policy bear point is downgraded to contained. Against that, the earnings-quality bear point is confirmed, cash conversion is promoted to a standing bear pillar, and the separation pillar has now spent four quarters at risk while its financing costs accumulate in the income statement.

Action: Trim. This is a price call on a business that is executing better than at any point in our coverage. We said last quarter that future return depends increasingly on another year of earnings delivery; the company delivered, and the share price took 23.0% of it while our fiscal 2028 estimate rose 3.6%. At $1,072.00 the shares require 22.2x fiscal 2028 earnings in twelve months simply to match the market, on an algorithm management twice declined to raise. Holders of a core position should take the operating vindication and reduce the weighting into it.